The key binary catalyst is FDA acceptance of the seralutinib NDA, which would unlock up to $125M in committed capital. Monitor for FDA filing decision in the coming weeks; acceptance would significantly extend the cash runway into a potential 2027 launch.
Drug in focus
GOSS drug pipeline →seralutinib
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (completed; missed primary endpoint)
- Time to market
- Target NDA submission September 2026; potential FDA approval Q3 2027 if accepted — but highly uncertain given the failed Phase 3.
- Next catalyst
- None dated
What to watchWatch for the public disclosure of the pre-NDA meeting outcome (mid-June 2026 meeting). If the FDA pushes back on filing, the stock could fall further. If the FDA allows the NDA submission to proceed, a September filing announcement could trigger a short-term bounce. Either way, this is a distressed penny stock, position sizing should account for potential total loss.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $11.69entry
- T+1 · 5d ago −3.85%α −3.50% · $11.24
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Gossamer Bio reported Q3 2026 results with a net loss of $48.1M ($7.36 per share), compared to a net loss of $48.2M ($16.92 per share) in Q3 2025. The NDA for seralutinib in PAH was submitted in September 2026, and the company has a structured private placement that could provide up to $125M upon FDA acceptance of the NDA. Cash stood at $51.2M as of September 30, 2026.
Key Financial Metrics
Key Facts
- NDA for seralutinib in PAH submitted to FDA in September 2026
- Net loss of $48.1M for Q3 2026 vs $48.2M in Q3 2025
- Cash, cash equivalents and marketable securities of $51.2M as of September 30, 2026
- Structured private placement: $25M upfront, up to $125M additional upon FDA acceptance of NDA
- 1-for-80 reverse stock split completed in September 2026
- Revenue from contracts with collaborators was $38.4M, up from $13.3M in Q3 2025, primarily from Chiesi termination
- R&D expenses decreased to $18.8M from $45.5M in Q3 2025
Financial Impact
Net loss of $48.1M; cash burn of $5.8M from $57.0M to $51.2M during Q3 2026
Risk Factors
- FDA may not accept the NDA for filing, which would prevent the $125M capital tranche
- Even if accepted, FDA approval is not guaranteed and the Phase 3 PROSERA study's statistical significance was characterized as a review issue
- Cash runway only into Q1 2027 without additional capital; the company is dependent on the NDA milestone for funding
- D. E. Shaw has been de-escalating its activist stake, now below 5%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001728117-26-000116 |
| Document: goss-20261110.htm | 0001728117-26-000116 |
| Document: 0001728117-26-000116-index-headers.html | 0001728117-26-000116 |
| Document: 0001728117-26-000116-index.html | 0001728117-26-000116 |
| Document: 0001728117-26-000116.txt | 0001728117-26-000116 |
| 8-K Data (Synthetic) | 0001728117-26-000116 |
Track record
20 reports on GOSS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.28% at T+60 after the Jun 17, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today S-3 Neutral 3/10 Entry $10.98 Now $10.98 −0.00% settles Feb 16
- Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $11.69 Now $10.98 −6.07% settles Feb 9
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $10.65 Now $10.98 +3.15% settles Feb 5
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $9.77 Now $10.98 +12.38% settles Feb 4
- Oct 29, 202618d ago SC 13D/A Bearish 5/10 Entry $10.38 Now $10.98 −5.78% settles Jan 28
- Oct 8, 20265w ago SC 13D/A Bearish 5/10 Entry $9.31 Now $10.98 −17.94% settles Jan 6
- Sep 28, 20267w ago SC 13D/A Bearish 6/10 Entry $11.58 Now $10.98 +5.18% settles Dec 23
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $11.69 Now $10.98 −6.07% settles Dec 16
- Sep 16, 20268w ago 8-K Neutral 4/10 Entry $11.94 Now $10.98 −8.04% settles Dec 11
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $10.73 Now $10.98 −2.33% settles Dec 7
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers